Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.
Healthcare IT Today
JANUARY 8, 2024
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. Riccardo Butta, President of the Americas at Stevanato Group In 2024, we can expect progress around men’s health, specifically in prostate cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
JUNE 20, 2023
Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.
Digital Health Global
SEPTEMBER 27, 2023
With these resources, Automera is well positioned to deploy our AUTAC platform toward the development of potentially transformative therapies.” Since our inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics, and digital health companies, as well as early-stage VC funds.
Society for Participatory Medicine
AUGUST 17, 2022
For a person like me, who is impacted by a rare, neurological, and incurable disease, it’s my mission to ensure that patients’ perspectives are represented early and throughout drug development. We plan to gather these stakeholders at the upcoming Huntington Study Group conference this November 3-5 in Tampa, FL, to develop next steps.
Digital Health Global
FEBRUARY 16, 2023
“Avilar is pioneering the next frontier in protein degradation and we are excited that our significant progress over the past year in discovering and advancing extracellular protein degraders has attracted this group of leading investors,” said Daniel Grau, CEO and President of Avilar Therapeutics.
Healthcare Innovation Consortium
OCTOBER 24, 2023
We aim to bring together relevant stakeholders, including payers, providers, patients groups, and biotech and when and where needed we cooperate with pharma, to be the one voice of the industry. The pipeline for new antibiotics is limited, which is partly due to how new drug development is funded.
Expert insights. Personalized for you.
144 
Let's personalize your content